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Materials and Methods: Between April 2008 and September 
2013, 33 patients with high grade glioma were treated with 
CRT using IMRT boosts in combination with HBO therapy. 
Twenty four (73%) patients have a tumor with WHO 
classification of Grade IV, and 9 (27%) patients have a Grade 
III. Before CRT, tumor resection was performed in 26 (79%) 
patients, and tumor biopsy was in 7 (21%) patients. The 
protocol of RT was as follows; first, three-dimensional 
conformal RT were delivered 40 Gy/20 fractions (fr)/daily 
2.0Gy to the GTV and surrounding edema plus 1.5 to 2.0cm as 
the clinical target volume extended (CTV-e). Continuously, 
the IMRT boosts using Cyberknife were delivered 28 Gy/8 
fr/daily 3.5 Gy to the GTV and 16 Gy/8 fr/daily 2.0 Gy to the 
surrounding edema defined as the clinical target volume 
annulus (CTV-a). HBO therapy was performed immediately 
before each IMRT boost session, and was a single treatment 
for 60 minutes in a monoplace HBO chamber pressured with 
100% oxygen to 2.0 atmospheres absolute. Temozolomide as 
a concurrent or adjuvant chemotherapy was administrated in 
29 (88%) patients. Feasibility and efficacy of this combined 
therapy were retrospectively analyzed.  
Results: Planned RT dose was completed in all patients, 
while HBO therapy was terminated in 2 (6%) patients due to 
aural pain of Grade 2 at first and second session. Radiation 
necrosis of the brain of Grade 2 occurred in 3 (9%) patients. 
Acute and late toxicities were mild, no Grade 3 or higher 
toxicity was observed in any of the patients. The median 
follow-up duration was 17 months. The median local 
progression-free survival time was 16 months. Median overall 
survival times were 23 months with Grade IV and 30 months 
with grade III, respectively. Eastern Cooperative Oncology 
Group (ECOG) performance status of 0-1 resulted in better 
overall survival rates (p<0.01). 
Conclusions: The combined therapy of CRT using IMRT boosts 
in combination with HBO therapy was a feasible and 
promising modality for high grade glioma, and the results 
justify further evaluation to clarify the benefits of this 
treatment regimen.  
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Purpose/Objective: The aim of the present analysis was to 
evaluate the recurrence pattern in patients with recurrent 
malignant glioma after re-irradiation with bevacizumab. 
Materials and Methods: Thirty-one patients with recurrent 
malignant glioma treated with re-irradiation and 
bevacizumab after previous chemoradiotherapy (according to 
EORTC/NCIC trial) and [18F]FET-PET and/or MRI confirmed 
recurrence were retrospectively analyzed. Bevacizumab was 
applied twice during fractionated re-irradiation (10 mg/kg, 
d1 + d15, median 36 Gy, 2 Gy single doses). Recurrence 
patterns were assessed by means of [18F]FET-PET and/or MRI. 
Results: Median follow-up was 34.0 months for all patients 
[95%-CI, 27.7-40.3] and median post-recurrence survival 10.8 
months [95%-CI, 9.2-12.4]. Concerning the recurrence 
patterns, 61.3% of these were located in-field (19 patients), 
22.6% were marginal (7 patients) and 16.1% ex-field (5 
patients). No influence on the recurrence pattern was 
observed according to sex, WHO grade, maintenance 
chemotherapy or MGMT methylation status whereas planning 
target volume (PTV) size had a significant influence on the 
recurrence pattern (p=0.032). PTV sizes > 75 ml were 
associated with a higher in-field recurrence rate and lower 
median post-recurrence progression-free survival (8.5 vs. 4.9 
months, p=0.016). 
Conclusions: After the administration of re-irradiation with 
bevacizumab the recurrence pattern seems to be mainly 
centrally located. The PTV size was the main predictor for a 
marginal/ex-field recurrence.  
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Purpose/Objective: The standard tools in the target volume 
delineation of glioblastoma multiforme (GBM) are 
gadolinium-enhanced T1-weighted (Gd-MRI) and T2-weighted 
MRI (T2-MRI); however, neither contrast enhancement nor 
edema are sufficient to accurately measure tumor extension 
in recurrent GBM. C11-methionine PET (MET-PET) is a well-
established technique for evaluating the tumor extent for the 
radiation treatment planning in brain tumor and there is a 
relationship in localization between the MET-PET uptake and 
the grade of malignancy in GBM. The purpose of this work is 
to investigate the recognition of the tumor extent and to 
define the optimal margin to Gd-MRI and T2-MRI in the re-
irradiation planning of recurrent GBM by comparison to MET-
PET. 
Materials and Methods: CT, MRI, and MET-PET were 
separately performed within 2 weeks in 25 patients with 
recurrent GBM for the re-irradiation planning. The Gd-MRI 
clinical target volume (CTV) (CTV-Gd) and the T2-MRI CTV 
(CTV-T2) were defined as the contrast-enhanced area on Gd-
MRI and the high intensity area on T2-MRI, respectively. We 
defined CTV x mm (x= 5, 10, 15, 20) as x mm outside the 
CTV. MET-PET CTV (CTV-MPET) was defined as the area of 
MET accumulation, which was higher than that of normal 
tissue on MET-PET. A threshold value of CTV-MPET for the 
tumor/normal tissue index of 1.3 was considered for 
malignant activity. We calculated the sensitivity and 
specificity of CTV-Gd and CTV-T2 by comparison to CTV-MPET 
served as the gold standard in this study. 
Results: The average CTV-MPET, CTV-Gd, and CTV-T2 volume 
were 59, 56, and 222 ml, respectively. There was no 
significant correlation between each type of the CTV in its 
size. Sensitivity of CTV-T2 5 mm (98%) was significantly 
higher than CTV-T2 (88%), and there was no significant 
difference in sensitivity between CTV-T2 5 mm and CTV-T2 
10, 15, and 20 mm. Sensitivity of CTV-Gd 20 mm (97%) was 
lower than that of CTV-T2 5 mm. The specificity of CTV-Gd 
and CTV-T2 significantly decreased in accordance with 
increases in the margin outside the CTV-Gd and CTV-T2. 
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Conclusions: In patients with recurrent GBM, CTV-Gd and 
CTV-T2 differed considerably from CTV-MPET. At least 5 mm 
margin to CTV-T2 would be necessary in the target volume 
delineation of recurrent GBM to cover CTV-MPET in the re-
irradiation planning. 
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Purpose/Objective: The aim of this study is to evaluate the 
reliability of MRI fusion for the determination of target 
volume when performing CT based intracranial stereotactic 
radiosurgery.  
Materials and Methods: Patients treated with CT based 
intracranial stereotactic radiosurgery with various diagnoses 
are included in the study. All patients were immobilized 
using stereotactic thermoplastic masks prior to simulation. 
The planning CT was obtained both with and without iv 
contrast with 1mm slice thickness. The images obtained were 
then fused with 3D, T1 weighted MR images with contrast by 
two different platforms (Eclipse 10.0, Velocity 3.0 rigid and 
Velocity 3.0 deformable). The target volume was contoured 
by the same physician in four different image sets (planning 
CT with iv contrast, planning CT fused with MRI by Eclipse 
software, planning CT fused with MRI with Velocity rigid 
fusion algorithm software, planning CT fused with MRI with 
Velocity deformable fusion algorithm software). The target 
volumes delineated on planning CT with iv contrast were 
determined as reference volume. The intersections of all 
volumes delineated with three different fusion algorithms 
were produced and ratios of the intersections were 
calculated. Values close to one was determined as the unit of 
similarity and were compared with Paired-Samples t test. The 
center of each target was determined and offsets were 
calculated according to the reference.  
Results: Eight intracranial targets were evaluated. All of the 
targets evaluated were clearly visualized in the planning CT 
with iv contast. Six of these lesions were metastases while 
the remaining two were meningioma. The median volume of 
the delineated targets on the planning CT with iv contrast 
was 9.53 cc. The intersecting volume with three different 
fusion algorithms (Eclipse fusion, Velocity rigid fusion and 
Velocity deformeable fusion) was 8.08, 6.74 and 6.84 cc 
respectively. The ratios of the intersections were 1.20, 1.42 
and 1.40 where all of these differences were significant 
(p=0.004, p=0.010 ve p=0.009). The maxiumum offset in each 
fusion was in Y axis and the most in velocity deformable 
fusion (mean 0.3 cm; 0.02-0.76cm). There was difference 
between offsets for the lesion which are close to or away 
from the bone. 
Conclusions: Determining the target volume with MRI fusion 
when performing CT based intracranial stereotactic 
radiosurgery may not be very reliable compared to obtaining 
a planning CT with iv contrast. Careful attention must be 
paid to this as this might affect not only the treatment 
outcomes but also the late toxicity.  
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Purpose/Objective: To analyse the survival after salvage 
radiosurgery and to identify the prognostic factors 
Materials and Methods: We retrospectively reviewed 87 
consecutive patients, with recurrent high-grade glioma, that 
underwent stereotactic radiosurgery between 1997 and 2010. 
We evaluated the survival after initial diagnosis and after re-
irradiation. The prognostic factors were analysed by bivariate 
and multivariate Cox regression model. 
Results: The median age was 48 years old. The primary 
histology included anaplastic astrocytoma (47%) and 
glioblastoma (53%). A margin dose of 18Gy was administered 
in the majority of cases (74%). The median survival after 
initial diagnosis was 21 months (39 months for anaplastic 
astrocytoma and 18.5 months for glioblastoma) and after re-
irradiation was 10 months (17 months for anaplastic 
astrocytoma and 7.5 months for glioblastoma). In the 
bivariate analyses the prognostic factors significantly 
associated with the survival after re-irradiation were: age, 
tumour and treatment volume at recurrence, recursive 
partitioning analyses classification, karnofsky performance 
score, histology, and margin to the planning target volume. 
Only the last four showed significant association in the 
multivariate analyses. 
Conclusions: stereotactic radiosurgery is a safe and may be 
an effective treatment option for selected patients diagnosed 
with recurrent high-grade glioma. The identified prognostic 
factors could help to individualise the treatment.  
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Purpose/Objective: Kaposi’s sarcoma (KS) is a low grade 
malignant vascular endothelial tumor which has a viral 
etiology; KS herpes virus (KSHV). It was found to be endemic 
in the Central and Southern Africa. Sporadic cases are found 
in the Mediterranean region. With the advent of HIV- AIDS 
epidemic, the incidence of Kaposi's sarcoma has increased. 
The Aim of the study is to determine the demographics of the 
disease, treatment and their outcomes. 
Materials and Methods: The study is a retrospective study of 
patients with Kaposi's sarcoma who presented to the unit 
from 2004-2013. It evaluated all histologically confirmed 
cases of KS for demographic information, HIV status, degree 
